- ►vpc.lt [PDF] G Merlini, V Bellotti - The New England journal of medicine, 2003 - nejm.highwire.org The amyloidoses constitute a large group of diseases in which misfolding of
extracellular protein has a prominent role. This dynamic process, which occurs
in parallel with or as an alternative to physiologic folding, generates ... Cited by 410 - Related articles - BL Direct - All 9 versions
- ►annals.org [PDF] M Skinner, V Sanchorawala, DC Seldin, LM … - Annals of internal medicine, 2004 - Am Coll Physicians Martha Skinner, MD; Vaishali Sanchorawala, MD; David C. Seldin, MD, PhD; Laura
M. Dember, MD; Rodney H. Falk, MD; John L. Berk, MD; Jennifer J. Anderson, PhD;
Carl O'Hara, MD; Kathleen T. Finn, RN, NP; Caryn A. Libbey, MD; Janice ... Cited by 259 - Related articles - All 17 versions
DC Seldin, EB Choufani, LM Dember, JF … - Clinical Lymphoma & Myeloma, 2003 - CIG Media Group Introduction In light chain–associated (AL) amyloidosis, immunoglobulin light
chains are deposited in tissues as fibrils leading to tissue damage and
multiorgan dysfunction. Organ failure is progres- sive and the median ... Cited by 76 - Related articles - BL Direct - All 2 versions
- ►hematologylibrary.org - Free from Publisher A Dispenzieri, MA Gertz, RA Kyle, MQ Lacy, … - Blood, 2004 - bloodjournal.hematologylibrary.org Primary systemic amyloidosis (AL) is a fatal plasma cell disorder. Pilot data
suggest survival is better in patients undergoing peripheral blood stem cell
transplantation (PBSCT), but the selection process makes the apparent ... Cited by 75 - Related articles - BL Direct - All 8 versions
V Sanchorawala, DG Wright, DC Seldin, RH … - Bone Marrow Transplantation, 2003 - nature.com A prospective randomized trial was conducted to study the timing of high-dose
intravenous melphalan and autologous stem cell transplantation (HDM/SCT) in AL
amyloidosis. In all, 100 newly diagnosed patients were randomized to ... Cited by 65 - Related articles - BL Direct - All 3 versions
MA Gertz, MQ Lacy, A Dispenzieri, SM Ansell, … - Bone Marrow Transplantation, 2004 - nature.com High-dose chemotherapy and autologous stem cell transplantation are used
increasingly to treat patients with light-chain-related amyloidosis (AL).
Treatment-related mortality is approximately 15%. To enable more patients ... Cited by 52 - Related articles - BL Direct - All 3 versions
DC Seldin, JJ Anderson, V Sanchorawala, K … - Blood, 2004 - bloodjournal.hematologylibrary.org Treatment of AL amyloidosis patients with high-dose melphalan chemotherapy
followed by autologous peripheral blood stem cell transplantation (HDM/SCT) can
produce hematologic complete responses (CRs) and improvement in organ ... Cited by 50 - Related articles - BL Direct - All 14 versions
- ►ucl.ac.uk [PDF] LM Dember, PN Hawkins, BPC Hazenberg, PD … - New England Journal of Medicine, 2007 - content.nejm.org From Boston University School of Medi- cine, Boston (LMD, MS); the National
Amyloidosis Centre, Royal Free Hospital, London (PNH, HJL); the University
Medical Center Groningen, University of Groningen, Groningen, the ... Cited by 48 - Related articles - BL Direct - All 11 versions
- ►asnjournals.org LM Dember - Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol The amyloidoses are a group of disorders in which soluble proteins aggregate and
deposit extracellularly in tissues as insoluble fibrils, causing progressive
organ dysfunction. The kidney is one of the most frequent sites of amyloid ... Cited by 39 - Related articles - BL Direct - All 7 versions
MA Gertz, MQ Lacy, A Dispenzieri - Blood reviews, 2004 - Elsevier An accurate diagnosis of amyloidosis and its subtype classification are
essential for disease prognostication and treatment. In primary amyloidosis,
overall median survival is approximately 2 years and may be less in ... Cited by 34 - Related articles - All 12 versions
